GAMMA Investing’s Sana Biotechnology SANA Stock Holding History

GAMMA Investing’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$921	Buy	+316	New	+$1.1K	﹤0.01%	4112
2026 Q2	–	Sell	-222	Closed	-$639	–	4215
2026 Q1	$639	Sell	222 -33	-13%	-$130	﹤0.01%	3913
2025 Q4	$1.04K	Buy	+255	New	+$1.14K	﹤0.01%	3780
2024 Q4	–	Sell	-88	Closed	-$366	–	3820
2024 Q3	$366	Sell	88 -13	-13%	-$68	﹤0.01%	3436
2024 Q2	$551	Sell	101 -82	-45%	-$653	﹤0.01%	3196
2024 Q1	$1.83K	Buy	183 +95	+108%	+$712	﹤0.01%	2772
2023 Q4	$483	Buy	+88	New	+$324	﹤0.01%	2973

Other funds holding SANA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's SANA Position: Q3 2026 in Review

GAMMA Investing opened a new position in Sana Biotechnology (SANA) in Q3 2026: 316 shares worth $921. The stake represents ﹤0.01% of the portfolio and ranks #4112 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in SANA as recently as Q1 2026.

GAMMA Investing first reported a position in SANA in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.83K in Q1 2024. 5 funds tracked by Wall St. Rank hold SANA as of Q3 2026.

GAMMA Investing held 316 shares of Sana Biotechnology worth $921 as of Q3 2026.
Sana Biotechnology was a new GAMMA Investing position in Q3 2026.
Sana Biotechnology made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4112 holding.
GAMMA Investing first reported a position in Sana Biotechnology in Q4 2023 and has held it in 7 quarters since.
GAMMA Investing's Sana Biotechnology position peaked at $1.83K in Q1 2024.
5 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.